Abstract 1603
Background
The first-in-human, ongoing phase I study of PF-06801591, a humanized IgG4 antibody to programmed cell death 1 (PD-1) receptor, consisted of a Part 1 dose escalation and Part 2 dose expansion. In Part 1, PF-06801591 was administered intravenously or SC with an acceptable safety profile and antitumor activity in several solid tumor types. Herein, we report on Part 2 where we further evaluated SC PF-06801591 in patients (pts) with NSCLC and UC.
Methods
Anti-PD-1/L1-naïve pts with NSCLC (n = 68) and UC (n = 38) received SC PF-06801591 300 mg q4w. NSCLC pts had ≤1 prior line of chemotherapy (CT) ± ≥1 ALK/EGFR mutation-directed therapies (if applicable) and UC pts had ≤2 lines of prior CT. Tumors were evaluated q8w by RECIST 1.1. Blood samples were collected for pharmacokinetic (PK) and immunogenicity assessments. Archival or baseline biopsies were evaluated by immunohistochemistry for PD-L1, RNA-seq, and whole exome sequencing.
Results
As of 27Dec2018, with median duration of treatment of 2.8 mos. in all 106 treated pts (55 still receiving treatment), 50.9% had treatment-related AEs (TRAEs) with 8.5% grade 3 or higher. Most common TRAEs were hyperthyroidism (9.4%), pruritus (6.6%), and increased amylase/lipase, anemia, hypothyroidism, pneumonitis, and rash (4.7% each). Treatment-emergent anti-drug antibodies were detected in 3 pts. With median follow-up of 5.1 mos. in 67 modified intent to treat (mITT) NSCLC pts, 11 (16.4%) pts achieved a partial response (PR) and 26 (38.8%) had stable disease (SD); the objective response rate (ORR) was 16.4% with 95% confidence interval (CI) 8.5-27.5% (25% in pts with ≥1% tumor cell PD-L1 expression). With median follow-up of 3.0 mos. in 37 mITT UC pts, 6 (16.2%) pts had a PR and 13 (35.1%) had SD; ORR was 16.2% (95% CI 6.2-32.0%). PK and biomarker data will be presented.
Conclusions
SC PF-06801591 given monthly was well tolerated, with minimal rates of injection site reactions and low incidence of immunogenicity. SC PF-06801591 demonstrated antitumor activity in NSCLC and UC pts at an early time point. The study is ongoing to further assess the durability of responses and long-term safety profile.
Clinical trial identification
NCT02573259.
Editorial acknowledgement
S. Mariani MD PhD of Engage Scientific Solutions, Southport, CT, funded by Pfizer and L. Chen.
Legal entity responsible for the study
Pfizer Inc.
Funding
Pfizer Inc.
Disclosure
B.C. Cho: Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): MOGAM Institute; Research grant / Funding (institution): Dong-A ST; Research grant / Funding (institution), Licensing / Royalties: Champions Oncology; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Yuhan; Advisory / Consultancy, Research grant / Funding (institution): Ono; Research grant / Funding (institution): Dizal Pharma; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Roche; Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Takeda; Shareholder / Stockholder / Stock options: TheraCanVac Inc; Shareholder / Stockholder / Stock options: Gencurix Inc; Shareholder / Stockholder / Stock options: Bridgebio Therapeutics. K. Penkov: Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Prestige Biopharma; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Tanvex. M. Korozan: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Regeneron. Y. Kulyaba: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Azaya Therapeutics; Research grant / Funding (institution): Celltrion; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Synta Pharmaceuticals; Research grant / Funding (institution): Tanvex. H.K. Ahn: Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Eisai; Honoraria (self): Ono; Honoraria (self): Roche. S. Odintsova: Full / Part-time employment: Complete Medical Technologies. J. Davda: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. A. Forgie: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. X. Wang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. R. Li: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. I.A. Jacobs: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. F. Kazazi: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. J. Chou: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. M.L. Johnson: Honoraria (institution), Research grant / Funding (institution): AstraZeneca; Honoraria (institution), Research grant / Funding (institution): Genentech/Roche; Honoraria (institution), Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (institution), Research grant / Funding (institution): Loxo; Honoraria (institution), Research grant / Funding (institution): Merck; Honoraria (institution), Research grant / Funding (institution): Mirati; Honoraria (institution), Research grant / Funding (institution): Sanofi; Honoraria (institution): Calithera; Honoraria (institution): Celgene; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): GenMab; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): StemCentrix; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Array BioPharma; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Adaptimmune; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Apexigen; Research grant / Funding (institution): BeiGene; Research grant / Funding (institution): BerGenBio; Research grant / Funding (institution): Birdie; Research grant / Funding (institution): Checkpoint Therapeutics; Research grant / Funding (institution): Corvus; Research grant / Funding (institution): Cytomx; Research grant / Funding (institution): Daiichi–Sankyo; Research grant / Funding (institution): Dynavax; Research grant / Funding (institution): G1 Therapeutics; Research grant / Funding (institution): Genocea; Research grant / Funding (institution): Gritstone; Research grant / Funding (institution): Hengrui Therapeutics; Research grant / Funding (institution): Lycera; Research grant / Funding (institution): Neovia; Research grant / Funding (institution): Syndax; Research grant / Funding (institution): Tarveda; Spouse / Financial dependant, contract lobbyist : Astellas; Spouse / Financial dependant, contract lobbyist : Otsuka Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic
Presenter: Anjuleta Kampitsi
Session: Poster Display session 3
Resources:
Abstract
6058 - Level of physical activity and nutritional status in cancer patients with fatigue: an exploratory cross-sectional study
Presenter: Patrick Jahn
Session: Poster Display session 3
Resources:
Abstract
1980 - Catheter related necrotizing fascitiis in haematological patients. Case report and implications for nursing
Presenter: Arianna Rosich Soteras
Session: Poster Display session 3
Resources:
Abstract
3984 - Everyday life with Long-term Chemotherapy Induced Peripheral Neuropathy among Patient in Adjuvant Treatment for Colorectal Cancer – a Multi Methods Study
Presenter: Marlene Jensen
Session: Poster Display session 3
Resources:
Abstract
2202 - Scalp cooler is effective in reducing chemotherapy-induced alopecia among breast cancer patients : a single institution experience
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
5942 - Nursing management of fatigue in cancer patients: mixed methods study
Presenter: Angela Tolotti
Session: Poster Display session 3
Resources:
Abstract
2930 - Awareness of Nursing Students about the Warning Signs of Cancer
Presenter: Hatice Yakar
Session: Poster Display session 3
Resources:
Abstract
2978 - Assessment of quality of life in patients with cancer and diabetes 2 in Northern Greece.
Presenter: STYLIANI MICHALOPOULOU
Session: Poster Display session 3
Resources:
Abstract
3400 - Radiation dose variables related to the causes of skin toxicities in women with breast cancer: a study proposal
Presenter: EULALIA PUJOL
Session: Poster Display session 3
Resources:
Abstract
2156 - How should the symptoms be managed after breast cancer surgery? An example of mobile app
Presenter: AYDANUR AYDIN
Session: Poster Display session 3
Resources:
Abstract